Cigna prior authorization for Q0224: Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate- to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to COVID-19 vaccination, 4500 mg
Code
Q0224
Description
Injection, pemivibart, for the pre-exposure prophylaxis only, for certain
adults and adolescents (12 years of age and older weighing at least 40
kg) with no known sars-cov-2 exposure, and who either have moderate-
to-severe immune compromise due to a medical condition or receipt of
immunosuppressive medications or treatments, and are unlikely to
mount an adequate immune response to COVID-19 vaccination, 4500
mg
Source
Master Precertification List
For Health Care Providers, Pg 93 Original policy
The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.
Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.
Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.
This website uses cookies to ensure you get the best experience on our website. Learn more
